RBC lifts Illumina target to $310 on clinical sales
Alpha Vantage · Investing.com India · · AI-summarised by FinFlash
RBC Capital has increased its price target for Illumina (NASDAQ: ILMN) shares to $310 from $230, while maintaining an Outperform rating, citing a multiple re-rating driven by clinical sales and positive catalysts, including the company being seen as an AI beneficiary. Despite customer purchasing dynamics creating near-term noise, RBC Capital believes the underlying thesis for Illumina has strengthened. The stock has seen an 80% return over the past year and is trading near its 52-week high, with InvestingPro analysis suggesting it remains undervalued.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.